Cimetidine-a clinical and pharmacokinetic study

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Duodenal ulceration is a common gastrointestinal condition.
• Cimetidine is a histamine H2-receptor antagonist used for treating duodenal ulcers.

Purpose of the Study:

• To evaluate the efficacy of six months of cimetidine therapy (800 mg or 1600 mg/day) in patients with duodenal ulceration.
• To assess the effects of cimetidine withdrawal on ulcer recurrence and symptoms.
• To investigate the pharmacokinetic profile of cimetidine during long-term treatment.

Main Methods:

• A study involving 19 patients with duodenal ulceration.
• Treatment with cimetidine at 800 mg or 1600 mg daily for up to six months.
• Monitoring of ulcer healing rates via clinical and endoscopic assessments.
• Pharmacokinetic analysis including elimination half-life, clearance, volume of distribution, and bioavailability.
• Assessment of symptom recurrence after abrupt cimetidine withdrawal.

Main Results:

• Ulcer healing rates were 63% at 3 months and 79% at 6 months.
• Extended treatment duration or higher dosage did not significantly improve healing rates.
• Abrupt cimetidine withdrawal led to severe symptom recurrence in 79% of patients.
• Pharmacokinetic studies revealed no drug accumulation or changes in the pharmacokinetic profile with long-term use.
• Inter-individual variations in response were not explained by pharmacokinetic differences.

Conclusions:

• Cimetidine demonstrates significant efficacy in healing duodenal ulcers.
• Long-term cimetidine therapy does not lead to drug accumulation.
• Abrupt cessation of cimetidine therapy is associated with a high rate of symptom recurrence.
• Pharmacokinetic parameters do not correlate with clinical or endoscopic response to cimetidine.